Surface Oncology is a clinical-stage immuno-oncology company focused on using its knowledge of the biological pathways critical to the immunosuppressive tumor microenvironment (TME) for the development of cancer therapies. The company's programs targets several components of the immunosuppressive TME. NZV930 and SRF617 are antibodies inhibiting cluster of differentiation, or CD, 73 and CD39, respectively, and illustrate how the company's knowledge of TME biology can be utilized across programs. SRF388 is an antibody targeting interleukin 27, an immunosuppressive cytokine in the TME that is overexpressed in certain cancers.
- ExchangeNASDAQ Stock Market
- SectorPharmaceuticals & Biotechnology
- CountryUnited States